CV Therapeutics, Inc.

CV Therapeutics, Inc. is a biopharmaceutical company focused primarily on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. The Company applies advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. It promotes Ranexa (ranolazine extended-release tablets), a small molecule drug that inhibits the late sodium current at therapeutic levels and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. In addition to its marketed products, the Company is developing other drug candidates, including regadenoson, a selective application to application (A2A)-adenosine receptor agonist, for potential use as a pharmacologic agent in myocardial perfusion imaging studies.